Skip to main content
Equibles
PAHC logo

PAHC · Phibro Animal Health Corp · Metrics

Track PAHC — free

Use PAHC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PAHC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$38.80 -1.01 (-2.54%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.62B
Shares
40.60M
Volume · Oct 23 102.89K Avg daily vol (3M) 225.64K

PAHC metrics

111 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$38.80
Market cap
$1.62B

Price action

20 metrics
Price change (1W)
+4.8%
Price change (30D)
+13.3%
Price change (3M)
+17.0%
Price change (6M)
-27.2%
Price change (YTD)
+6.6%
Price change (1Y)
-0.9%
Trailing year
Price change (5Y)
+76.5%
52-week high
$59.58
52-week low
$28.52
Change from 52-week high
-33.2%
Change from 52-week low
+39.6%
Annualized volatility
53.9%
Annualized volatility (3M)
30.8%
Beta
0.7
RSI (14D)
65.5
Price vs SMA 50
+9.0%
Price vs SMA 200
-3.6%
Avg volume (3M)
226,548
Relative volume
1.1
Average dollar volume
$8.25M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
40.60M

Valuation

12 metrics
P / E (TTM)
16.4
Trailing earnings · reciprocal yield 6.1%
PEG ratio
0.8
EV / revenue
1.4×
reciprocal yield 71.0%
EV / EBITDA
8.7×
reciprocal yield 11.5%
EV / EBIT
11.0×
reciprocal yield 9.1%
P / sales
1.0×
reciprocal yield 95.3%
P / book
4.1
reciprocal yield 24.2%
FCF yield
0.6%
TTM · current market cap
Buyback yield
—
P / FCF
161.5
reciprocal yield 0.6%
P / operating cash flow
23.1
reciprocal yield 4.3%
Earnings yield
6.3%

Historical valuation

8 metrics
P / E historical average (3Y)
54.4×
reciprocal yield 1.8%
P / E historical average (5Y)
45.5×
reciprocal yield 2.2%
EV / revenue historical average (3Y)
1.2×
reciprocal yield 83.4%
EV / revenue historical average (5Y)
1.1×
reciprocal yield 88.3%
EV / EBIT historical average (3Y)
14.7×
reciprocal yield 6.8%
EV / EBIT historical average (5Y)
13.9×
reciprocal yield 7.2%
EV / EBITDA historical average (3Y)
10.1×
reciprocal yield 9.9%
EV / EBITDA historical average (5Y)
9.6×
reciprocal yield 10.4%

Dividends & buybacks

7 metrics
Dividend yield
1.2%
Trailing 12 months
Payout ratio
19.5%
Shareholder yield
1.2%
Dividend / share (TTM)
$0.48
Dividend growth YoY
+0.0%
Dividend growth streak
0
Last ex-dividend
2026-09-02

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-27

Profitability

9 metrics
Gross margin
33.8%
Operating margin
12.8%
Trailing 12 months
Net margin
6.6%
Gross profit (TTM)
$512.51M
Operating profit (TTM)
$194.40M
Net income (TTM)
$99.72M
Trailing 12 months
Diluted EPS (TTM)
$2.43
FCF margin
0.6%
Effective tax rate
27.4%

Per share

11 metrics
Revenue per diluted share (TTM)
$37.06
Gross profit per diluted share (TTM)
$12.51
Operating profit per diluted share (TTM)
$4.75
EBITDA per diluted share (TTM)
$6.00
Net income per diluted share (TTM)
$2.43
Operating cash flow per diluted share (TTM)
$1.68
Free cash flow per diluted share (TTM)
$0.24
Capital expenditures per diluted share (TTM)
$1.44
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.04
Book value per share
$-1.14

Growth

11 metrics
Revenue growth YoY
+4.8%
Year over year
Net income growth YoY
+26.0%
Revenue (TTM)
$1.52B
Trailing 12 months
EPS growth YoY
+20.9%
Shares change YoY
+0.8%
Year over year · more shares
Revenue CAGR (3Y)
+15.8%
Revenue CAGR (5Y)
+12.7%
EPS CAGR (3Y)
+44.2%
EPS CAGR (5Y)
+12.6%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-12.3%

Quality

14 metrics
Return on equity
25.9%
Return on assets
6.6%
Debt / equity
1.7
Current ratio
3.0
EBITDA (TTM)
$245.91M
Free cash flow (TTM)
$9.87M
Quick ratio
1.3
Interest coverage
4.2
Net debt / EBITDA
2.2
Return on invested capital
15.6%
Trailing 12 months
Net cash
−$543.07M
Latest balance sheet
Cash & equivalents
$61.42M
Total assets
$1.50B
Total debt
$620.52M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$68.95M
Capital expenditures (TTM)
$59.09M
R&D (TTM)
—
SG&A (TTM)
$318.12M
Stock compensation (TTM)
$1.60M
R&D / revenue
—
Stock compensation / revenue
0.1%

Ownership (13F)

9 metrics
13F filers
208
13F filer change QoQ
-51
Institutional ownership
51.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+5.3%
Holder tenure
15.9
Price vs estimated holder cost
-4.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
14.2%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1069899 CUSIP 71742Q106 13F (30d) 30 filings 30 filers Visit website Investor relations